New Cancer Detection Tool Focuses on Children
A new technology, NV-VPAC1™, may help doctors more accurately diagnose childhood cancers, according to Utah-based developer NuView Life Sciences. Today’s diagnostic tools often rely on invasive procedures, like surgical biopsies, or scans that use radiation to pinpoint cancers in children accurately, says the company.
For example, if a child has suspected kidney cancer, doctors would only need a voided urine specimen to test for the presence of and positively identify shed cancer cells.
NV-VPAC1, a peptide analog by pairing a diagnostic imaging positron emitter, uses a shed cell assay that targets the vasoactive intestinal peptide receptor type 1. This analog was originally developed by Drs. Madhukar Thakur and Leonard Gomella at Thomas Jefferson University.
Paul Crowe, CEO of NuView Life Sciences, commented in a press release issued on February 8, 2021, “Many of the current diagnostic tests and treatment options for pediatric cancers are based on information derived from methods used in adult patients and may affect kids negatively."
"When our clinical trials resume [post-COVID-19], we hope to show that our proprietary technology, NV-VPAC1, actually helps make cancer diagnosis easier, detected earlier, and lead to more precise treatments that are individualized for younger patients.”
Founded in 2005, NuView Life Sciences is a clinical-stage oncology company located in Park City, Utah, advancing the way cancer is diagnosed and treated in our modern healthcare system.